Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry
RHEUMATOLOGY, cilt.59, sa.11, ss.3324-3329, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 59 Sayı: 11
- Basım Tarihi: 2020
- Doi Numarası: 10.1093/rheumatology/keaa121
- Dergi Adı: RHEUMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Sayfa Sayıları: ss.3324-3329
- Anahtar Kelimeler: colchicine, resistant, intolerant, FMF, anakinra, canakinumab, anti-IL1, HELIOS, FAMILIAL MEDITERRANEAN FEVER, CANAKINUMAB, ANAKINRA, CHILDREN, EFFICACY
- Eskişehir Osmangazi Üniversitesi Adresli: Hayır
Özet
Objectives. FMF is a prototype of autoinflammatory diseases associated with excess IL1 production. Anti-IL1 treatments are the first-line alternatives in colchicine-resistant/intolerant FMF patients. We aimed to investigate the efficacy and safety of anti-IL1 treatment in paediatric FMF patients in our local [Hacettepe univErsity eLectronlc research fOrmS (HELIOS)] registry.